Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy

International Journal of Hematology

Volumn 91, Issue 4, 2010, Pages 630-635

  Kudo, Kazuko ^a   Hama, Asahito ^b   Kojima, Seiji ^b   Ishii, Ruriko ^c   Morimoto, Akira ^d   Bessho, Fumio ^e   Sunami, Shosuke ^f   Kobayashi, Naoyuki ^g   Kinoshita, Akitoshi ^h   Okimoto, Yuri ⁱ   Tawa, Akio ^j   Tsukimoto, Ichiro ^k  

^a SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e KYORIN UNIVERSITY   (Japan)

^f NARITA RED CROSS HOSPITAL   (Japan)

^g JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ CHIBA CHILDREN'S HOSPITAL   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION   (Japan)

^k SAISEIKAI YOKOHAMASHI TOBU HOSPITAL   (Japan)

more..

Author keywords

Acute megakaryoblastic leukemia; Cytarabine; GATA1; Mosaic Down syndrome

Indexed keywords

CYTARABINE; TRANSCRIPTION FACTOR GATA 1;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOWN SYNDROME; DRUG MEGADOSE; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; HUMAN; INFANT; LOBAR PNEUMONIA; LOW DRUG DOSE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELOPOIESIS; OVERALL SURVIVAL; PANCREATITIS; PRESCHOOL CHILD; RETROSPECTIVE STUDY;

ANTIMETABOLITES, ANTINEOPLASTIC; CHILD, PRESCHOOL; CYTARABINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN SYNDROME; FEMALE; GATA1 TRANSCRIPTION FACTOR; HUMANS; INFANT; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; MALE; MOSAICISM; PREVALENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 77954491064     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0549-1     Document Type: Article

References (18)

1. Devlin L, Morrison PJ. Accuracy of the clinical diagnosis of Down syndrome. Ulster Med J. 2004;73:4-12.
2. Kojima S, Sako M, Kato K, et al. An effective chemotherapeutic regimen for acute myeloid leukaemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia. 2000;14:786-791
3. Kudo K, Kojima S, Tabuchi K, et al. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukaemia: the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2007;25:5442-5447
4. O'Brien MM, Taub JW, Chang MN, et al. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. J Clin Oncol. 2008;26:414-420
5. Gamis AS, Woods WG, Alonzo TA, et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. J Clin Oncol. 2003;21:3415-3422
6. Abildgaard L, Ellebaek E, Gustafsson G, et al. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature. Ann Hematol. 2006;85(5):275-280
7. Creutzig U, Reinhardt D, Diekamp S, et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia. 2005;19:1355-1360
8. Rao A, Hills RK, Stiller C, et al. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol. 2006;132:576-583
9. Simon JH, Tebbi CK, Freeman AI, et al. Acute megakaryoblastic leukaemia associated with mosaic Down's syndrome. Cancer. 1987;60:2515-2520
10. Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27:4007-4013
11. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958;53:457-481
12. Iizuka A, Nagao T. A case of acute megakaryoblastic leukaemia associated with mosaic Down's syndrome. Jpn J Pediatr Hematol. 1988;92:1598-1603
13. Kurosaki M, Sugita K, Ohneda S, et al. A case of megakaryoblastic leukaemia after recovering from transient abnormal myelopoiesis with mosaic Down's syndrome. Jpn J Pediatr Hematol. 1990;4:114-119
14. Doyle JJ, Thorner P, Poon A, et al. Transient leukaemia followed by megakaryoblastic leukaemia in a child with mosaic Down syndrome. Leukemia Lymphoma. 1995;17:345-350
15. Palmer CG, Blouin JL, Bull MJ, et al. Cytogenetic and molecular analysis of a ring (21) in a patient with partial trisomy 21 and megakaryocytic leukaemia. Am J Med Genet. 1995;57:527-536
16. Punnett HH, Dampier C. Trisomy 11 limited to trisomy 21 cells in a mosaic Down syndrome child with acute myeloid leukaemia. Med Pediatr Oncol. 2003;41:69-70.
17. Hasle H, Abrahamsson J, Arola M, et al. Myeloid leukemia in children 4 years or olDer with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. Leukemia. 2008;22:1428-1430
18. Sandoval C, Pine SR, Guo Q, et al. Tetrasomy 21 transient leukaemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature. Pediatr Blood Cancer. 2005;44:85-91.